Nimodipine
Pre-eclampsia
FDA Office of Orphan Products DevelopmentSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Pre-eclampsia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid FANG HE | Phase 4 | BBB |
FUROSEMIDE University of California, Irvine | Phase 4 | BB |
Metformin University of Oulu | Phase 3 | BB |
Nifedipine University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
ATENOLOL University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
LABETALOL University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
Ferumoxytol University of Wisconsin, Madison | D | |
2-(Furan-2-ylmethylamino)-5-sulfamoylbenzoic acid University of California, Irvine | Phase 4 | NR |
Same molecule, other indications
Nimodipine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →